Galmed Pharmaceuticals
GLMD
31 hedge funds and large institutions have $30.1M invested in Galmed Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0.04% less ownership
Funds ownership: 0.2% → 0.17% (-0.04%)
9% less funds holding
Funds holding: 34 → 31 (-3)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
41% less capital invested
Capital invested by funds: $50.9M → $30.1M (-$20.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$823K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$782K |
| 3 |
JP Morgan Chase
New York
|
+$180K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$127K |
| 5 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
+$75.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.14M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$4.69M |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
-$572K |
| 4 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$337K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$180K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $4.78K | – | – | – |
|
27
Bank of America
Charlotte,
North Carolina
| $2K | -$5.02K | -5 | -63% |
|
|
BCM
28
Bourgeon Capital Management
Darien,
Connecticut
| $2K | +$3.01K | +3 | New |
|
|
FHA
29
Flagship Harbor Advisors
Boston,
Massachusetts
| $1K | – | – | – |
|
|
RFA
30
Reilly Financial Advisors
La Mesa,
California
| $1K | – | – | – |
|
|
VC
31
Vivo Capital
Palo Alto,
California
| – | -$7.14M | -5,396 | Closed |
|
|
MIH
32
Meitav Investment House
Bene-Beraq,
Israel
| – | -$4.69M | -3,551 | Closed |
|
|
PAM
33
Premier Asset Management
Chicago,
Illinois
| – | -$572K | -433 | Closed |
|
|
34
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$180K | -179 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$38K | -29 | Closed |
|
36
UBS Group
Zurich,
Switzerland
| – | -$9K | -7 | Closed |
|
GLMD Hedge Fund Activity: Q3 2019 in Review
31 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2019, worth a combined $30.1M — down 41% from $50.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GLMD and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Ibex Investors, adding an estimated $823K. The largest seller was Vivo Capital, exiting entirely with an estimated $7.14M sold.
- 31 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2019, down from 34 in Q2 2019.
- Funds reported $30.1M of Galmed Pharmaceuticals stock for Q3 2019, down 41% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q3 2019 and 6 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2019 was Ibex Investors, an estimated $823K added.
- The largest Galmed Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $7.14M sold.
Based on aggregated 13F filings for Q3 2019.